Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Names Dr. Allen R. Nissenson as Chief Medical Officer

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Names Dr. Allen Nissenson as Chief Medical Officer

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer.  Dr. Nissenson will join Sentien’s executive team and oversee the clinical development of Sentien’s lead product, SBI-101.  Dr. Nissenson serves as an Emeritus Professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles, Emeritus Chief Medical Officer of DaVita Kidney Care, and a member of the Board of Directors of Angion Biomedica Corp and Rockwell Medical, Inc. Read More >

Sentien Biotechnologies Names Richard Ganz as Executive Chairman

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Names Richard Ganz as Executive Chairman

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the appointment of Richard Ganz as Executive Chairman.  Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he has filled for the past nine years, as well as work closely with CEO Brian Miller and Sentien’s management team. Read More >

Sentien Biotechnologies, Inc. Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies, Inc. Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced that it has opened enrollment in its Phase 1/2 trial of SBI-101 for adult patients with acute kidney injury (AKI).  This trial is Sentien’s first clinical program.
Read More >

Sentien Biotechnologies, Inc. Announces $12 Million Series A Financing

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies, Inc. Announces $12 Million Series A Financing

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced today that it has closed a $12 million Series A investment round. The financing was co-led by Boehringer Ingelheim Venture Fund USA, Inc. (BIVF USA) and BioInnovation Capital, and joined by Chiesi Ventures, MBL Venture Capital Co., Ltd, and Mass Medical Angels. The Series A round will be used to fund initial clinical development of Sentien’s SBI- 101 for the treatment of acute kidney injury (AKI).
Read More >